| Objective To evaluate the efficacy and safety of Qianggu Capsule and vitamin D for the healing of osteoporotic fracture and to provide clinical reference in choosing drugs for patients with osteoporotic fracture. Methods Databases including PubMed, SCI, The Cochrane Library, China National Knowledge Infrastructure (CNKI), Chinese Biomedical Databases (CBM), Weipu China Science and Technology Journal Databases (VIP) and WanFang Data were searched to collect data of randomized controlled trials (RCTs) related Qianggu Capsule and vitamin D for the treatment of osteoporotic fracture from inception to the 27th of January 2017. Two reviewers independently screened literature, extracted data and evaluated the risk of bias of included studies. Meta-analysis was performed using RevMan 5.3 software. Results A total of 3 RCTs were included, which involved 510 patients. The results of meta-analysis showed that compared with vitamin D, Qianggu Capsule could significantly shorten the recovery time of fracture (MD＝–3.68，95％CI –4.60，–2.76, P<0.00001] and significantly increase bone mineral density (BMD) at femoral neck after treatment (MD＝0.03, 95％CI 0.01, 0.04, P=0.0002). The number of mild adverse reactions in patients received Qianggu Capsule was significantly higher than that in patients received vitamin D. The differences between two groups were statistically significant (OR＝23.89, 95％CI 4.56, 125.11, P=0.0002]. Conclusion Current evidence shows that, compared with vitamin D, Qianggu Capsule could effectively shorten the recovery time of fracture and increase the bone mineral density in patients with osteoporotic fracture. However, attention should be paid to gastrointestinal adverse reactions. |